UK markets open in 6 hours 24 minutes

Biophytis SA (BPTS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.68-0.39 (-4.30%)
At close: 11:24AM EDT
8.71 +0.03 (0.35%)
After hours: 05:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.07
Open8.74
Bid8.70 x 800
Ask11.00 x 900
Day's range8.68 - 8.93
52-week range8.40 - 18.50
Volume959
Avg. volume2,760
Market cap99.848M
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)-3.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia

    Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the studySarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product PARIS and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”) is a clinical-stage biot

  • Globe Newswire

    Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of Justice

    PARIS and CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces that the judge in charge of overseeing

  • Globe Newswire

    Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

    PARIS and CAMBRIDGE, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19 today announces new positive p